Ben practices corporate, commercial, and regulatory law with a focus on the life sciences, technology, manufacturing, retail, and healthcare sectors.
Ben advises on a wide range of matters including corporate governance, commercial agreements, mergers & acquisitions, corporate reorganizations, and product regulatory compliance and enforcement.
Within his corporate and commercial practice, Ben routinely supports organizations by drafting and negotiating a broad spectrum of agreements, including those related to supply of goods and services, research collaborations, and intellectual property licensing. He assists companies in corporate restructurings, mergers & acquisitions, and developing procedures for supply chain due diligence. He frequently advises charities and not-for profits, including hospitals, foundations, and community health centres, on governance best practices and on navigating sensitive matters that may involve reputational risk.
In his product regulatory practice, Ben provides strategic guidance to companies entering or operating in the Canadian market, including on product compliance, labelling, warnings, advertising, recalls, and responding to enforcement action from some of Canada’s key product regulators, including Health Canada and Innovation, Science, and Economic Development Canada. Ben has particular experience in assisting both domestic and international companies that manufacture, import, and/or sell medical devices, pharmaceuticals, foods, and natural health products. He also has significant experience advising on sale of good and consumer protection legislation across the country, assisting manufacturers and online retailers develop compliant contracts of sale, terms of service, and warranty documentation.
Prior to attending law school, Ben completed a Master of Science degree in Immunology. His research focused on developing new immunosuppression medication for kidney transplant patients.
Ben is a member of Medtech Canada and a co-author of LexisNexis’ Canadian Food and Drug Legislation & Commentary, 2025 Edition.
Experience
- Counsel to Guardian Capital Group Limited in its $1.67 billion go-private transaction with Desjardins Global Asset Management Inc.
- Counsel to Guardian Capital Group Limited in its $1.67 billion go-private transaction with Desjardins Global Asset Management Inc.
